

IX BIOPHARMA LTD
(Incorporated in Singapore)
(Company Registration No. 200405621W)

ISSUE AND ALLOTMENT OF SHARES PURSUANT TO EXERCISE OF WARRANTS

The Board of Directors (the “**Board**”) of iX Biopharma Ltd. (the “**Company**”), and together with its subsidiaries, the “**Group**”) wishes to announce that on 30 June 2026, the Company has allotted and issued 4,423,414 new ordinary shares pursuant to the exercise of warrants at the exercise price of S\$0.06 per warrant share, following which the number of issued shares of the Company has increased from 1,063,788,999 shares to 1,068,212,413 shares.

The new ordinary shares rank *pari passu* in all respects with the existing shares of the Company and are expected to be listed and quoted on the Singapore Exchange Securities Trading Limited on or around 2 July 2026. Pursuant to the aforesaid exercise of warrants, a cumulative total of 32,035,349 warrants, representing 55.70% of all warrants previously issued, have now been exercised and there are 25,474,130 outstanding warrants with an exercise price of S\$0.06 for each warrant share.

Pursuant to the Warrant Conditions, ***the Warrants will expire on Friday, 17 July 2026 at 5.00 p.m.***, being the Market Day immediately preceding the second anniversary of the date of issue of the Warrants.

The last day for trading in the Warrants on the SGX-ST will be Friday, 10 July 2026, and trading will cease with effect from 9.00 a.m. on 13 July 2026. The Warrants will then be de-listed from Official List of the SGX-ST with effect from 9.00 a.m. on 20 July 2026.

AFTER THE CLOSE OF BUSINESS AT 5.00 P.M. ON FRIDAY, 17 JULY 2026, ANY SUBSCRIPTION RIGHTS UNDER THE WARRANTS WHICH HAVE NOT BEEN EXERCISED WILL LAPSE AND EVERY WARRANT WILL THEREAFTER CEASE TO BE VALID FOR ANY PURPOSE WHATSOEVER.

Warrant holders may refer to the Company’s announcement on 16 June 2026 or <https://www.ixbiopharma.com/warrants/> for instruction on how to exercise their warrants.

BY ORDER OF THE BOARD

Eddy Lee Yip Hang
Chairman & CEO
30 June 2026

*This announcement has been reviewed by the Company’s Sponsor, UOB Kay Hian Private Limited (the “**Sponsor**”).*

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinion made or reports contained in this announcement.*

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01, UE Square, Singapore 239920, telephone: (65) 6590 6881.